1. Home
  2. MDWD vs GHG Comparison

MDWD vs GHG Comparison

Compare MDWD & GHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • GHG
  • Stock Information
  • Founded
  • MDWD 2000
  • GHG 2004
  • Country
  • MDWD Israel
  • GHG China
  • Employees
  • MDWD N/A
  • GHG N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • GHG Hotels/Resorts
  • Sector
  • MDWD Health Care
  • GHG Consumer Discretionary
  • Exchange
  • MDWD Nasdaq
  • GHG Nasdaq
  • Market Cap
  • MDWD 208.2M
  • GHG 232.5M
  • IPO Year
  • MDWD 2014
  • GHG 2018
  • Fundamental
  • Price
  • MDWD $18.63
  • GHG $2.11
  • Analyst Decision
  • MDWD Strong Buy
  • GHG
  • Analyst Count
  • MDWD 2
  • GHG 0
  • Target Price
  • MDWD $35.00
  • GHG N/A
  • AVG Volume (30 Days)
  • MDWD 66.7K
  • GHG 30.4K
  • Earning Date
  • MDWD 08-14-2025
  • GHG 08-19-2025
  • Dividend Yield
  • MDWD N/A
  • GHG 4.62%
  • EPS Growth
  • MDWD N/A
  • GHG N/A
  • EPS
  • MDWD N/A
  • GHG 0.15
  • Revenue
  • MDWD $19,213,000.00
  • GHG $184,055,595.00
  • Revenue This Year
  • MDWD $20.64
  • GHG $19.02
  • Revenue Next Year
  • MDWD $25.71
  • GHG $8.26
  • P/E Ratio
  • MDWD N/A
  • GHG $14.58
  • Revenue Growth
  • MDWD N/A
  • GHG N/A
  • 52 Week Low
  • MDWD $14.14
  • GHG $1.93
  • 52 Week High
  • MDWD $22.51
  • GHG $3.40
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 41.12
  • GHG 42.13
  • Support Level
  • MDWD $17.60
  • GHG $2.11
  • Resistance Level
  • MDWD $19.12
  • GHG $2.40
  • Average True Range (ATR)
  • MDWD 0.79
  • GHG 0.17
  • MACD
  • MDWD -0.15
  • GHG -0.04
  • Stochastic Oscillator
  • MDWD 37.84
  • GHG 1.48

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About GHG GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share

GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The hotel network of the company comprised approximately 4,059 hotels with nearly 302,497 rooms in China, covering all centrally administrated municipalities and cities throughout all provinces and autonomous regions in China. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The company operates solely in China and generates all its revenue from China itself.

Share on Social Networks: